Telix and Ekalia, an IBA-Framatome joint venture, are collaborating to establish a dedicated U.S. source for astatine-211, a critical isotope for targeted alpha therapy. This secures Telix's long-term access for its glioblastoma pipeline and leverages its existing manufacturing infrastructure.
Telix and Ekalia (an IBA-Framatome JV) are partnering to produce astatine-211 (211At) in the U.S., a scarce alpha-emitting isotope vital for targeted alpha therapy (TAT). This collaboration is significant because it secures a long-term, priority supply of 211At for Telix's alpha therapy pipeline, particularly for its TLX102-Tx candidate for glioblastoma, a severe brain cancer. The installation of an IBA alpha-beam cyclotron at Telix's RLS Radiopharmacies site near Philadelphia leverages Telix's existing infrastructure and could lead to further installations. For traders, this reduces supply chain risk for Telix's promising alpha therapy programs, potentially accelerating development and commercialization, while also expanding IBA's market for specialized cyclotrons. The long-term implication is enhanced stability and potential growth for Telix's TAT segment, with a short-term positive sentiment boost.